JP2019131569A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019131569A5 JP2019131569A5 JP2019043934A JP2019043934A JP2019131569A5 JP 2019131569 A5 JP2019131569 A5 JP 2019131569A5 JP 2019043934 A JP2019043934 A JP 2019043934A JP 2019043934 A JP2019043934 A JP 2019043934A JP 2019131569 A5 JP2019131569 A5 JP 2019131569A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- keratitis
- disease
- diastereomer
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010023332 Keratitis Diseases 0.000 claims 3
- 200000000018 inflammatory disease Diseases 0.000 claims 3
- 206010064930 Age-related macular degeneration Diseases 0.000 claims 2
- 208000002780 Macular Degeneration Diseases 0.000 claims 2
- -1 hydrate Substances 0.000 claims 2
- 230000003287 optical Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010013774 Dry eye Diseases 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002458 infectious Effects 0.000 claims 1
- 230000035168 lymphangiogenesis Effects 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 230000002980 postoperative Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (3)
- 下記の化合物リストから選択される化合物、或いはその医薬的に許容される塩、水和物、溶媒和物、光学異性体又はジアステレオマーを含む、眼炎症性疾患を治療するための医薬組成物。
- 前記眼炎症性疾患は、ブドウ膜炎、ドライアイ、角膜炎、アレルギー性眼疾患、感染性角膜炎、疱疹角膜炎、角膜脈管形成、リンパ脈管新生、網膜炎、脈絡膜炎、急性多発性小板状色素上皮症、ベーチェット病、術後角膜創傷治癒、萎縮型及び滲出型加齢性黄斑変性症（ＡＲＭＤ）から選択される、請求項１記載の医薬組成物。
- 全身炎症性疾患、痛み、免疫学的増強障害、及び関節リウマチから選択される少なくとも１種を治療するための医薬組成物であって、
下記の化合物リストから選択される化合物、或いはその医薬的に許容される塩、水和物、溶媒和物、光学異性体又はジアステレオマーを含む、前記医薬組成物。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361773773P | 2013-03-06 | 2013-03-06 | |
| US61/773,773 | 2013-03-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017157335A Division JP6496786B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019131569A JP2019131569A (ja) | 2019-08-08 |
| JP2019131569A5 true JP2019131569A5 (ja) | 2019-11-14 |
| JP6672500B2 JP6672500B2 (ja) | 2020-03-25 |
Family
ID=50382628
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561536A Active JP6196327B2 (ja) | 2013-03-06 | 2014-03-04 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157335A Active JP6496786B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157334A Active JP6602351B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2019043934A Active JP6672500B2 (ja) | 2013-03-06 | 2019-03-11 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015561536A Active JP6196327B2 (ja) | 2013-03-06 | 2014-03-04 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157335A Active JP6496786B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
| JP2017157334A Active JP6602351B2 (ja) | 2013-03-06 | 2017-08-17 | 眼炎症性疾患の治療のためのホルミルペプチド受容体２のアゴニストの使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9850264B2 (ja) |
| EP (2) | EP2964213B1 (ja) |
| JP (4) | JP6196327B2 (ja) |
| KR (2) | KR102227201B1 (ja) |
| CN (2) | CN105007909B (ja) |
| AR (1) | AR095034A1 (ja) |
| AU (3) | AU2014225992B2 (ja) |
| BR (2) | BR122017004254B1 (ja) |
| CA (2) | CA3133264A1 (ja) |
| CL (3) | CL2015002485A1 (ja) |
| ES (1) | ES2835825T3 (ja) |
| HK (1) | HK1219657A1 (ja) |
| IL (3) | IL241012B (ja) |
| MX (1) | MX364916B (ja) |
| PH (3) | PH12015501858B1 (ja) |
| RU (2) | RU2663911C2 (ja) |
| SG (2) | SG11201507113RA (ja) |
| TW (1) | TWI616200B (ja) |
| WO (1) | WO2014138037A1 (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE040145T2 (hu) * | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| JP2015520130A (ja) * | 2012-04-16 | 2015-07-16 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体２調節物質としての（２−ウレイドアセトアミド）アルキル誘導体 |
| WO2013171687A1 (en) | 2012-05-16 | 2013-11-21 | Actelion Pharmaceuticals Ltd | 1-(p-tolyl)cyclopropyl substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
| CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
| CA3133264A1 (en) | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
| CN107714683A (zh) | 2013-03-06 | 2018-02-23 | 阿勒根公司 | 用于治疗皮肤病的甲酰基肽受体2的激动剂的用途 |
| AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
| JP6653253B2 (ja) * | 2013-07-16 | 2020-02-26 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体モジュレーターとしてのｎ−尿素置換アミノ酸の誘導体 |
| EP3022188B1 (en) | 2013-07-18 | 2017-06-07 | Actelion Pharmaceuticals Ltd | Piperazine substituted bridged spiro[2.4]heptane derivatives as alx receptor agonists |
| AR097279A1 (es) | 2013-08-09 | 2016-03-02 | Actelion Pharmaceuticals Ltd | Derivados de benzimidazolil-metil urea como agonistas del receptor de alx |
| US9663457B2 (en) | 2014-04-09 | 2017-05-30 | Allergan, Inc. | Carbamoyl hydrazine derivatives as formyl peptide modulators |
| BR112016027133A8 (pt) | 2014-05-21 | 2021-06-29 | Allergan Inc | derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso |
| EP3271327A4 (en) | 2015-03-19 | 2018-11-21 | University of Maryland, Baltimore | Runx2 transcription factor inhibitors and uses thereof |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| CN109715602A (zh) * | 2016-03-28 | 2019-05-03 | 阿勒根公司 | 苯基脲衍生物作为n-甲酰肽受体调节剂 |
| CN109641857A (zh) * | 2016-04-12 | 2019-04-16 | 阿勒根公司 | 作为n-甲酰基肽受体调节剂的苯基脲衍生物 |
| RU2768587C2 (ru) | 2016-10-06 | 2022-03-24 | Дайити Санкио Компани, Лимитед | Производное мочевины |
| CN109134533B (zh) | 2017-06-27 | 2020-08-11 | 维眸生物科技（上海）有限公司 | 一种含磷化合物及其制备和应用 |
| CN107814773B (zh) * | 2017-11-13 | 2020-05-22 | 西安交通大学 | 含有喹唑啉酮的二芳基脲类化合物及其制备方法和应用 |
| RU2712229C2 (ru) * | 2018-05-17 | 2020-01-27 | Закрытое акционерное общество "Институт экспериментальной фармакологии" | Эфиры тригидроксигептаеновой кислоты в качестве агонистов fpr2 рецептора |
| KR102429281B1 (ko) * | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
| IT202100004964A1 (it) * | 2021-03-03 | 2022-09-03 | Univ Degli Studi Di Bari Aldo Moro | Agonisti del recettore fpr2 (formyl peptide receptor 2) e loro uso nel trattamento del disturbo dello spettro autistico. |
| JP2022151437A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 網膜炎治療薬。 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
| JPS63232846A (ja) | 1987-03-20 | 1988-09-28 | Haruo Ogura | 新規な固定相担体 |
| AU667995B2 (en) * | 1993-02-15 | 1996-04-18 | Bayer Aktiengesellschaft | New pseudopeptides having an antiviral action |
| US6423689B1 (en) * | 1997-12-22 | 2002-07-23 | Warner-Lambert Company | Peptidyl calcium channel blockers |
| AU6909300A (en) * | 1999-08-20 | 2001-03-19 | Merck & Co., Inc. | Substituted ureas as cell adhesion inhibitors |
| EP1162194A1 (en) | 2000-06-06 | 2001-12-12 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use |
| DE10063008A1 (de) | 2000-12-16 | 2002-06-20 | Merck Patent Gmbh | Carbonsäureamidderivate |
| JP2005538152A (ja) * | 2002-09-05 | 2005-12-15 | ニューロサーチ、アクティーゼルスカブ | ジアリール誘導体及びこれをクロライドチャネル遮断剤として使用する方法 |
| US7943137B2 (en) * | 2002-11-07 | 2011-05-17 | Takeda Pharmaceutical Company Limited | FPRL1 ligands and use thereof |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| KR20060130064A (ko) | 2003-11-07 | 2006-12-18 | 아카디아 파마슈티칼스 인코포레이티드 | 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, ｆｐｒｌ1의 용도 |
| US7820673B2 (en) | 2003-12-17 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Urea derivative, process for producing the same, and use |
| WO2006065755A2 (en) | 2004-12-13 | 2006-06-22 | Glaxo Group Limited | Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists |
| WO2007076055A2 (en) * | 2005-12-22 | 2007-07-05 | Entremed, Inc. | Compositions and methods comprising proteinase activated receptor antagonists |
| US20080008694A1 (en) * | 2006-07-05 | 2008-01-10 | Elgebaly Salwa A | Methods to prevent and treat diseases |
| US7884180B2 (en) * | 2006-09-18 | 2011-02-08 | Compugen Ltd | Peptides which bind to G protein-coupled receptors |
| WO2009097997A1 (de) | 2008-02-07 | 2009-08-13 | Sanofi-Aventis | Substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung |
| US20100035932A1 (en) * | 2008-08-07 | 2010-02-11 | Schepetkin Igor A | Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof |
| KR20100101054A (ko) * | 2009-03-07 | 2010-09-16 | 주식회사 메디젠텍 | 세포핵에서 세포질로의 ｇｓｋ３의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 ｇｓｋ３ 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물 |
| WO2011163502A1 (en) | 2010-06-24 | 2011-12-29 | Allergan, Inc. | Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity |
| AU2011336973A1 (en) * | 2010-12-03 | 2013-07-11 | Allergan, Inc. | Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity |
| EP2673263A1 (en) | 2011-02-11 | 2013-12-18 | Allergan, Inc. | Novel 1-(1-oxo-1,2,3,4-tetrahydroisoquinolin-7-yl)urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| US8653299B2 (en) | 2011-03-17 | 2014-02-18 | Allergan, Inc. | Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| AU2012271562A1 (en) | 2011-06-17 | 2014-01-30 | Allergan, Inc. | D -serine for the treatment of visual system disorders |
| EP2731931A1 (en) * | 2011-07-11 | 2014-05-21 | Allergan, Inc. | Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| HUE040145T2 (hu) | 2011-10-26 | 2019-02-28 | Allergan Inc | N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok |
| US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
| US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
| US8729096B2 (en) | 2012-02-16 | 2014-05-20 | Allergan, Inc. | Imidazolidine-2,4-dione derivatives as N-formyl peptide receptor 2 modulators |
| JP2015520130A (ja) | 2012-04-16 | 2015-07-16 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | ホルミルペプチド受容体２調節物質としての（２−ウレイドアセトアミド）アルキル誘導体 |
| CA3133264A1 (en) * | 2013-03-06 | 2014-09-12 | Allergan, Inc. | Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases |
-
2014
- 2014-03-04 CA CA3133264A patent/CA3133264A1/en active Pending
- 2014-03-04 BR BR122017004254-8A patent/BR122017004254B1/pt active IP Right Grant
- 2014-03-04 EP EP14712888.8A patent/EP2964213B1/en active Active
- 2014-03-04 WO PCT/US2014/020245 patent/WO2014138037A1/en active Application Filing
- 2014-03-04 MX MX2015011593A patent/MX364916B/es active IP Right Grant
- 2014-03-04 KR KR1020157024036A patent/KR102227201B1/ko active IP Right Grant
- 2014-03-04 CN CN201480012204.5A patent/CN105007909B/zh active Active
- 2014-03-04 SG SG11201507113RA patent/SG11201507113RA/en unknown
- 2014-03-04 EP EP20205401.1A patent/EP3795148A1/en active Pending
- 2014-03-04 JP JP2015561536A patent/JP6196327B2/ja active Active
- 2014-03-04 AU AU2014225992A patent/AU2014225992B2/en active Active
- 2014-03-04 RU RU2015136774A patent/RU2663911C2/ru active
- 2014-03-04 US US14/196,047 patent/US9850264B2/en active Active
- 2014-03-04 BR BR112015021371-5A patent/BR112015021371B1/pt active IP Right Grant
- 2014-03-04 ES ES14712888T patent/ES2835825T3/es active Active
- 2014-03-04 CA CA2898301A patent/CA2898301C/en active Active
- 2014-03-04 SG SG10201801471RA patent/SG10201801471RA/en unknown
- 2014-03-04 RU RU2018127997A patent/RU2768730C2/ru active
- 2014-03-04 CN CN201910497947.0A patent/CN110279684B/zh active Active
- 2014-03-04 KR KR1020207023766A patent/KR102290134B1/ko active IP Right Grant
- 2014-03-06 AR ARP140100732A patent/AR095034A1/es not_active Application Discontinuation
- 2014-03-06 TW TW103107761A patent/TWI616200B/zh active
-
2015
- 2015-08-24 PH PH12015501858A patent/PH12015501858B1/en unknown
- 2015-09-01 IL IL241012A patent/IL241012B/en active IP Right Grant
- 2015-09-04 CL CL2015002485A patent/CL2015002485A1/es unknown
-
2016
- 2016-07-04 HK HK16107693.7A patent/HK1219657A1/zh unknown
-
2017
- 2017-07-21 US US15/656,766 patent/US10208071B2/en active Active
- 2017-08-17 JP JP2017157335A patent/JP6496786B2/ja active Active
- 2017-08-17 JP JP2017157334A patent/JP6602351B2/ja active Active
- 2017-10-06 CL CL2017002526A patent/CL2017002526A1/es unknown
- 2017-10-06 CL CL2017002527A patent/CL2017002527A1/es unknown
-
2018
- 2018-05-28 AU AU2018203719A patent/AU2018203719B2/en active Active
- 2018-11-27 IL IL263314A patent/IL263314B/en active IP Right Grant
-
2019
- 2019-01-22 US US16/254,438 patent/US10899780B2/en active Active
- 2019-03-11 JP JP2019043934A patent/JP6672500B2/ja active Active
- 2019-09-06 AU AU2019226215A patent/AU2019226215B2/en active Active
-
2020
- 2020-02-07 PH PH12020500285A patent/PH12020500285A1/en unknown
- 2020-02-07 PH PH12020500286A patent/PH12020500286A1/en unknown
- 2020-03-11 IL IL273208A patent/IL273208A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131569A5 (ja) | ||
| IL263314A (en) | Use of Formula 2 receptor agonists for the treatment of ocular inflammatory diseases | |
| JP2020502047A5 (ja) | ||
| JP2015523546A5 (ja) | ||
| EA202090553A1 (ru) | Производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения | |
| JP2020500862A5 (ja) | ||
| JP2018035142A5 (ja) | ||
| JP2017105793A5 (ja) | ||
| MA51916A (fr) | Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide | |
| JP2018516904A5 (ja) | ||
| JP2017528503A5 (ja) | ||
| JP2006526031A5 (ja) | ||
| JP2018531218A5 (ja) | ||
| JP2019516739A5 (ja) | ||
| JP2019531279A5 (ja) | ||
| JP2020532547A5 (ja) | ||
| JP2015510941A5 (ja) | ||
| RU2009136911A (ru) | Соединения, представляющие собой стиролильные производные, для лечения офтальмических заболеваний и расстройств | |
| JP2019529514A5 (ja) | ||
| JP2019519533A5 (ja) | ||
| RU2489433C2 (ru) | Производное циклобутилпурина, агент, активирующий ангиогенез, агент, активирующий образование просвета, агент, активирующий рост нейронов, и лекарственное средство | |
| JP2007504235A5 (ja) | ||
| JP2023011735A5 (ja) | ||
| JP2021508318A5 (ja) | ||
| JP2010514733A5 (ja) |